# Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

> **NCT06939166** · EARLY_PHASE1 · RECRUITING · sponsor: **Tianjin Huanhu Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorders
- Myasthenia Gravis
- Multiple Sclerosis
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Autoimmune Encephalitis

## Interventions

- **DRUG:** UCAR T-cell

## Key facts

- **NCT ID:** NCT06939166
- **Lead sponsor:** Tianjin Huanhu Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2026-04
- **Final completion:** 2027-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06939166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06939166, "Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06939166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*